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OBJECTIVES The purpose of this study was to assess the quality of the management of infective
endocarditis.
BACKGROUND Although many guidelines on the management of infective endocarditis exist, the quality of
this management has not been evaluated.
METHODS We collected data on all patients (116) hospitalized with infective endocarditis over 1 year in
all hospitals in the Rhoˆne-Alpes region (France).
RESULTS Prophylactic antibiotics were not given before infective endocarditis to 8/11 cardiac patients
at risk and who underwent an at risk procedure. Among the 55 cardiac patients at risk and
with fever and who consulted a physician, blood cultures were not performed before antibiotic
therapy was initiated for 32 patients. In-hospital antibiotic therapy was incorrect for 23
patients. The portal of entry was not treated for 16/61 patients with an accessible portal of
entry. Among the 19 patients who had severe heart failure or fever persisting more than 2
weeks in spite of antibiotic therapy and who could have undergone early surgery, surgery was
delayed for five, and not performed for three. Overall, the average score was 15/20.
CONCLUSIONS More information on the management of infective endocarditis should be widely dissemi-
nated to the physicians’ and the dentists’ communities and to the patients at risk. (J Am Coll
Cardiol 1999;33:788–93) © 1999 by the American College of Cardiology
Numerous studies have reported the main characteristics of
infective endocarditis, but most of these studies were retro-
spective, and the cases were collected over a period of several
years (1–14). These studies have not shown dramatic
changes in the incidence or in the profile of infective
endocarditis despite the decreased incidence of rheumatic
heart disease, marked advances in medical and surgical
treatment and antibiotic prophylaxis recommendations (15–
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24). Its prognosis remains severe (25). Although many
guidelines on the management of infective endocarditis
exist, the management has not been evaluated. We thus
collected data on all patients (n 5 116) hospitalized with
infective endocarditis between November 1, 1990 and
October 31, 1991 in all hospitals (university, community or
private) in the Rhoˆne-Alpes region (France).
METHODS
This study was part of a larger prospective study on the
epidemiology of infective endocarditis which had been
approved by the French National Commission on Comput-
ing and Freedom (25). The methods have been fully
described elsewhere, and are briefly reported here (25).
For the present study, information was retrospectively
collected on all patients living in the Rhoˆne-Alpes region
(France) and hospitalized for infective endocarditis between
November 1, 1990 and October 31, 1991 in all public—
university (n 5 8) or community (n 5 26)—or private (n 5
10) hospitals located in the region (116 patients). The
von Reyn et al. diagnostic criteria for infective endocarditis
were modified to take into account echocardiographic find-
ings and macroscopic observations made by cardiac surgeons
(Table 1) (1).
For each patient the following information was recorded:
● Gender and age;
● History of heart disease, prosthetic valve, previous epi-
sode(s) of infective endocarditis;
● Current infective endocarditis: location, symptoms and
physical signs, echocardiographic findings, number of
positive blood cultures, causative microorganism, pre-
sumed portal of entry, surgical operation, lethality.
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All medical charts were reviewed by one of us (M.O.R.),
and data were extracted using a specific form. Another
investigator (F.D.) double-checked the data in a 10%
random sample of the medical charts. There were fewer
than 1% discrepancies, all minor.
The evaluation of the management of infective endocar-
ditis was limited to the medical attitudes considered as
having consensus in 1990, that is:
Quality of the antibiotic prophylaxis before the present
episode of infective endocarditis: it was evaluated only
in patients with a iatrogenic (i.e., due to a dental or a
medical procedure) portal of entry and for whom the
information was available; antibiotic prophylaxis was
considered correct if it conformed with the recom-
mendations issued by the French Federation of Car-
diology in 1984 (26): type of cardiac disease, type of at
risk procedure, dosage, route and type of antibiotics; it
was considered incorrect if it did not conform with at
least one of the cited features; no score was given since
it is not quality of management of infective endocar-
ditis stricto sensu, but quality of prophylaxis of infec-
tive endocarditis;
Prescription of blood cultures and/or hospitalization
before prescribing antibiotics: it was evaluated only in
patients with known valvular heart disease and fever
and who went to a physician; the diagnostic process
was considered correct (score 5 1) when the physician
prescribed one or more blood cultures and/or re-
quested hospitalization before prescribing any antibi-
otics; it was considered incorrect (score 5 0) when
neither blood cultures nor hospitalization were per-
formed before prescribing any antibiotics (27,28);
Quality of the management of the portal of entry: the
portal of entry was considered certain when the same
microorganism was found in that portal of entry and
in the blood cultures; it was considered presumed:
● Either when a lesion was found and was compatible with
the microorganism isolated in the blood cultures (e.g., an
intestinal polyp and Streptococcus bovis in the blood cul-
tures); or
● When there had been a dental or a medical procedure
within 3 months before infective endocarditis and the
microorganism isolated in the blood cultures was com-
patible with the location of the procedure (e.g., dental
scaling and Streptococcus sanguis in the blood cultures);
Management of the found or presumed portal of entry
was considered correct (score 5 1) when the portal of
entry was eradicated during the hospitalization (e.g.,
extraction of a tooth with an apical granuloma in a
patient with IE due to Streptococcus sanguis); it was
considered incorrect (score 5 0):
● Either when the portal of entry was not searched for,
although the microorganism had been isolated in the
Table 1. Criteria for Infective Endocarditis
Definite infective endocarditis
Direct evidence of infective endocarditis based on macroscopy and/or histology from surgery or autopsy, and/or bacteriology (Gram
stain or culture) of valvular vegetation or peripheral embolus
Probable infective endocarditis
A. Persistently positive blood cultures* plus one of the following:
1. New regurgitant murmur, or
2. Predisposing heart disease and vascular phenomena† (at least two), or
3. Predisposing heart disease and echocardiographic vegetation, or
4. Vascular phenomena† (at least two) and echocardiographic vegetation
B. Negative or intermittently positive blood cultures‡ plus one of the following:
1. Fever and new regurgitant murmur and vascular phenomena† (at least two), or
2. Fever and predisposing heart disease and vascular phenomena† (at least two) and echocardiographic vegetation
Possible infective endocarditis
A. Persistently positive blood cultures* plus one of the following:
1. Predisposing heart disease, or
2. Vascular phenomena† (at least two)
B. Negative or intermittently positive blood cultures‡ plus all three of the following:
1. Fever,
2. Predisposing heart disease, and
3. Vascular phenomena† (at least two)
Rejected infective endocarditis
A. Endocarditis unlikely, alternate diagnosis generally apparent
B. Endocarditis likely, empiric antibiotic therapy warranted
C. Culture-negative endocarditis diagnosed clinically, but excluded by surgery or postmortem
*At least two blood cultures performed, with 100% positive for two or three, or at least 70% positive if four or more. †Petechiae, splinter hemorrhages, conjunctival hemorrhages,
Roth spots, Osler’s nodes, Janeway lesions, aseptic meningitis, glomerulonephritis and pulmonary, central nervous system, coronary or peripheral emboli. ‡Any rate of blood
culture positivity that does not meet the definition of persistently positive Nota bene; a serological assay can lead to bacteriological diagnosis (Rickettsia, Chlamydia and so forth).
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blood cultures (e.g., no dental pantography performed in
a patient with Streptococcus sanguis in the blood cultures);
or
● When the found or presumed portal of entry was not
eradicated during the hospitalization;
Quality of the antibiotic therapy of infective endocarditis
during hospitalization: apyrexia was defined as a rectal
temperature #37°C in the morning and #37.5°C in
the evening; fever was defined as a rectal temperature
.37°C in the morning or .37.5°C in the evening;
antibiotic therapy was considered correct (score 5 1)
when it complied with published recommendations
(29,30): antibiotics dosage, route, number, synergy
and duration of treatment; it was considered incorrect
(score 5 0):
● Either when at least one of the cited features did not
comply with these recommendations; or
● When the treatment had not been adapted (type, dosage,
and so forth of antibiotics) to the course of the fever (fever
persisting more than 1 week);
Cardiac surgical treatment during the acute (antibiotic
therapy) phase of infective endocarditis: it was evalu-
ated only in patients in whom the clinical status
should have required cardiac surgery:
● Severe heart failure (Killip class 3 or 4) (31–35); and/or
● Persistence of fever more than 2 weeks after the beginning
of correct antibiotic therapy and with no infectious
metastatic location (28,32,35);
Surgical treatment was considered correct (score 5 1)
when patients requiring surgery were operated on; it
was considered incorrect (score 5 0) otherwise;
Surveillance during hospitalization: it was considered
correct (score 5 1) when, at discharge, the patient had
had apyrexia for at least 1 week, and had no signs of
congestive heart failure, and had stable or improved
cardiac auscultation and echocardiography features; it
was considered incorrect (score 5 0) otherwise;
For each patient, a global quality score was calculated by
dividing the figures found for the items applicable to
that patient by the maximal possible score for that
patient; a mean score was then calculated for the
whole group.
RESULTS
The main characteristics of the population are presented in
Table 2.
Antibiotic prophylaxis before infective endocarditis. A
portal of entry was found or presumed for 77 patients.
Information about antibiotic prophylaxis was available for
17/19 patients with a iatrogenic (including dental proce-
dures) portal of entry. Antibiotic prophylaxis was performed
correctly for three patients. Rightly, six patients received no
antibiotic prophylaxis: three patients had no known heart
disease; three patients with known valvular heart disease
underwent a procedure that was not considered to be at risk
Table 2. Characteristics of 116 Patients With
Infective Endocarditis
Characteristic n %
Whole treatment outside a university
hospital
40 34
Initial admission, hospital
University 41 35
Community 61 53
Private 14 12
Initial admission, department
Cardiology 59 51
General internal medicine 21 18
Emergency 9 8
Infectious diseases 8 7
Intensive care 4 3
Other 15 13
Gender (men/women) 80/36 69/31
Age
,51 years 39 33
51 to 67 years 38 33
.67 years 39 33
Known underlying heart disease 59 51
Valve prosthesis 15 13
History of infective endocarditis 8 7
Debilitated ground* 45 39
Diagnosis
Certain 37 32
Probable 55 47
Possible 24 21
Location
Mitral 47 41
Aortic 33 28
Mitral and aortic 13 11
Right heart 6 5
Right and left heart 4 3
Unknown 13 11
Microorganism
Streptococcus 77 66
Staphylococcus 16 14
Other 10 9
Unknown 13 11
Certain or presumed portal of entry 77 66
Surgical intervention during the
initial hospital stay
33 28
Surgical intervention while infective
endocarditis bacteriologically active
19 16
Complications† 81 70
Heart failure 37 32
*Diabetes mellitus; cancer; chronic enolism; hepatic cirrhosis; chronic renal insuffi-
ciency; chronic respiratory insufficiency; immunosuppressive therapy; splenectomy;
chronic hemopathy; intravenous drug abuse. †Heart failure; cardiogenic shock; septic
shock; embolism; acute renal failure; infective spondylodiskitis; decompensated
diabetes; decompensated cirrhosis.
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(cardiac catheterization, central venous catheter and periph-
eral venous catheter). For eight patients, antibiotic prophy-
laxis was not used although it should have been (removal of
an infected pacemaker: one patient; procedure at risk of
infective endocarditis for patients with a heart disease at risk
of infective endocarditis: seven patients).
Prescription of blood cultures and/or hospitalization
before prescribing antibiotics. Among the 55 patients
with known valvular heart disease and fever and who
consulted a physician, 10 patients had blood cultures per-
formed before antibiotic therapy was initiated and 10 other
patients were immediately hospitalized. Blood cultures were
not performed before antibiotic therapy was initiated for 32
patients (six of whom had prosthetic cardiac valves). For the
remaining three patients blood cultures were performed,
and these were positive, but the results were not well used
(no hospitalization, no parenteral antibiotic therapy and no
antibiotics at all).
Overall, 64% (35/55) of the patients in whom this feature
was analyzable did not have a good quality of diagnosis.
Antibiotic therapy. Antibiotic therapy was incorrect for 23
of the 112 (20%) patients for whom all data were available:
marked underdosage of beta-lactamins, for example, amoxi-
cillin 3 g/day for a patient weighing 70 kg: seven patients;
antibiotics not adapted to the microorganism or to the
antibiogram: six patients; antibiotics not adapted to the
course of the fever (no change of the dosage and/or of the
antibiotic despite persistent fever for more than 1 week): six
patients; insufficient length of antibiotic course: three pa-
tients; insufficient number of associated antibiotics: one
patient.
Search for and treatment of portal of entry. The portal of
entry was not at all searched for in two patients. The portal
of entry was not treated before hospital discharge for 16 of
the 61 patients (26%) with a curable portal of entry
(intestinal polyps: seven patients; dental lesions: eight pa-
tients; polyps in the maxillary sinus: one patient).
Overall, 29% (18/63) of the patients in whom this feature
was analyzable did not have a good quality of management
of portal of entry.
Cardiac surgical treatment. Among the 19 patients who
would have required surgery (severe heart failure: 10 pa-
tients; persistent fever for more than two weeks after the
beginning of suitable antibiotic therapy: seven patients;
both: two patients), eight received incorrect surgical treat-
ment (42%). Surgery was unduly delayed for five patients:
persistent fever; three patients; severe heart failure and
persistent fever: two patients. Three patients were not
operated on: one patient with severe heart failure was still
alive at 2 years; two deceased patients may have benefited
from surgery (one had fever for 5 months despite several
changes in antibiotic therapy; one was operated on in
emergency after having been discharged from hospital,
although the fever had persisted for 5 weeks despite anti-
biotic therapy and four embolic episodes had occurred).
In-hospital surveillance. Among the 103 patients who left
the hospital after the initial phase, seven (7%) were dis-
charged in error: two had clinical and echocardiographic
signs of prosthesis dehiscence, one had persisting fever, one
had been apyretic for 5 days only, one had noncompensated
cardiac failure, one had had a progressively increasing
cardiac murmur and one had had progressively increasing
dilation of the left ventricle. Four of these patients had a
complication in the month following discharge (one relapse
of infective endocarditis and three cases of severe heart
failure necessitating surgery) and two during the first 6
months (one death due to cerebral hemorrhage and one
severe heart failure necessitating surgery).
Overall. Globally, scores were obtainable in only 61%
[(55 1 112 1 63 1 19 1 103)/(116z5)], mainly because an
item was not applicable to some patients, sometimes be-
cause data were missing.
The mean overall score was 75%, that is, 15/20; on
average, in a patient, 75% of the management of infective
endocarditis was correct. Two patients were excluded be-
cause there was no applicable score. Among the remaining
114 patients, 44 (38%) had the maximal possible score
(100%).
The score was not different according to the specialty of
the medical ward the patients were first admitted to:
cardiology: 15.0/20; general internal medicine: 15.2/20;
intensive care: 15.0/20; infectious diseases: 14.9/20. Also, it
was not different according to the type of hospital the
patients were first admitted to: university hospitals: 15.9/20;
community hospitals: 14.5/20; private hospitals: 14.5/20.
Finally, the score was not different in patients alive at 2 years
(15.0/20) and in those deceased at 2 years (14.7/20).
DISCUSSION
Although guidelines on the prevention and management of
infective endocarditis exist, it seems from our results that
compliance with these guidelines is poor.
Methodological quality of the study. Because the medical
charts were reviewed by only one investigator, the data
extraction form was very precise and complete. The double-
checking of 10% of the medical charts disclosed less than 1%
discrepancies, which were all minor. Thus, we are rather
confident about the quality of our data.
Antibiotic prophylaxis of infective endocarditis. Al-
though apparent failure of antibiotic prophylaxis has been
reported (36), its efficacy has been reported at between 50%
and 90% (37–39), and antibiotic prophylaxis has been
reported to be cost-effective (40). Although on a country-
wide scale, low efficacy prophylaxis has a little impact
(between 60 and 120 events avoided for 1,500 patients
treated per year in France [37]), for an individual patient it
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is worthwhile, and its use for patients undergoing high risk
dental procedures is not challenged. However, the absence
of an overall consensus does not make the physicians’ task
easy, and compliance of dentists and physicians with rec-
ommendations for the prevention of infective endocarditis is
low (15). In our study, for eight out of 11 patients with a
iatrogenic portal of entry necessitating antibiotic prophy-
laxis, it was not administered. In agreement with our results,
several studies in France, the USA and the U.K. showed
that dentists and general practitioners varied in their knowl-
edge of the risk factors for infective endocarditis and in their
use of antibiotic prophylaxis, often despite knowing the
recommendations in their countries (41–44).
Propositions for improving the quality of care of infec-
tive endocarditis. Can the compliance with guidelines be
improved? The authors of a study in the U.K. suggested that
general practitioners should be supplied with self-adhesive
stickers to be placed at the front of the medical notes of all
patients at risk (43). In France a summary of the recom-
mendations of a consensus conference held in 1992 was sent
to all dentists and general practitioners (45). In addition the
French Federation of Cardiology is distributing a new
prophylaxis card. A survey of the incidence of infective
endocarditis is planned after this card has been in use for 5
years.
The unacceptably low rate of blood cultures before
initiation of antibiotics (60% of the patients at risk in our
series) needs to be improved. Regular reminders of the need
for blood cultures in cardiac patients at risk before initiating
a course of antibiotics should be sent to general practitio-
ners. Also, similar to what is done for the surveillance of
anticoagulant treatment, patients at risk of infective endo-
carditis could be given a prescription for blood cultures to be
used when they have fever lasting more than 3 days without
having to consult their physician.
The need for discussion between the clinician in charge of
the patient and the microbiologist is highlighted by the high
percentage of patients (20%) in our series who did not
received the correct antibiotic therapy. Similarly, discussion
between the cardiologist, the microbiologist and the cardiac
surgeon is needed, because, although some indications for
surgery are fully accepted, some are not (e.g., large vegeta-
tions, controlled heart failure, recent neurological compli-
cations). In our series 40% of the patients who could have
been operated on early either had unduly delayed surgery or
no surgery.
Although portals of entry may be more often found
nowadays (25) than previously (46,47), a systematic search is
not always performed. In a series of 53 patients with
infective endocarditis due to Streptococcus bovis (48), the
large bowel was not investigated in 19% of the patients. In
addition, curable portals of entry are not always correctly
treated. This was so for 19% of the patients in our series,
and for five out of 27 patients with colonic tumors in the
previously cited series (48).
Conclusions. The overall management of infective endo-
carditis was compliant with the guidelines for only 38% of
our patients. These results demonstrate that better informa-
tion for patients, dentists and physicians is needed. This
information should be simple and rediffused at regular
intervals. We believe that this study should be repeated in
other health care settings.
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